Agency Forms Undergoing Paperwork Reduction Act Review, 57831-57833 [2021-22695]
Download as PDF
<![CDATA[
jspears on DSK121TN23PROD with NOTICES1
Federal Register / Vol. 86, No. 199 / Tuesday, October 19, 2021 / Notices
OMB Control Number: 3060–0950.
Title: Bidding Credits for Tribal
Lands.
Form Number: N/A.
Type of Review: Extension of a
currently approved collection.
Respondents: Business or other forprofit entities, not-for-profit institutions,
and state, local or tribal government.
Number of Respondents: 5
respondents; 5 responses.
Estimated Time per Response: 10
hours.
Frequency of Response: On occasion
reporting requirement and
recordkeeping requirement.
Obligation to Respond: Required to
obtain or retain benefits. Statutory
authority for this information collection
is contained in 47 U.S.C. 151, 154(i),
303(r), and 303(j)(3) and (4) of the
Communications Act of 1934, as
amended.
Total Annual Burden: 100 hours.
Total Annual Cost: $270,000.
Needs and Uses: The Commission
will be submitting this expiring
information collection after this
comment period to the Office of
Management and Budget (OMB) for
approval of an extension request.
From June 2000 to August 2004, the
Commission adopted various
rulemakings in which a winning bidder
seeking a bidding credit to serve a
qualifying tribal land within a particular
market must:
• Indicate on the long-form
application (FCC Form 601) that it
intends to serve a qualifying tribal land
within that market;
• Within 180 days after the filing
deadline for the long-form application,
amend its long-form application to
identify the tribal land it intends to
serve and attach a certification from the
tribal government stating that:
(a) The tribal government authorizes
the winning bidder to site facilities and
provide service on its tribal land;
(b) The tribal area to be served by the
winning bidder constitutes qualifying
tribal land;
(c) The tribal government has not and
will not enter into an exclusive contract
with the applicant precluding entry by
other carriers, and will not
unreasonably discriminate among
wireless carriers seeking to provide
service on the qualifying tribal land; and
(d) Provide certification of the
telephone penetration rates
demonstrating that the tribal land has a
penetration level at or below 85 percent.
The rulemakings also require what
each winning bidder must do.
In addition, it also requires that a
winning bidder seeking a credit in
excess of the amount calculated under
VerDate Sep<11>2014
17:51 Oct 18, 2021
Jkt 256001
the Commission’s bidding credit must
submit certain information; and a final
winning bidder receiving a higher credit
must provide within 15 days of the third
anniversary of the initial grant of its
license, file a certification that the credit
amount was spent on infrastructure to
provide wireless coverage to qualifying
tribal lands, which also includes a final
report prepared by an independent
auditor verifying that the infrastructure
costs are reasonable to comply with our
build-out requirements.
Federal Communications Commission.
Marlene Dortch,
Secretary, Office of the Secretary.
57831
Control Group, a group acting in
concert, to acquire voting shares of
Resource Bancshares, Inc., and thereby
indirectly acquire voting shares of
Resource Bank, National Association,
both of DeKalb, Illinois.
Board of Governors of the Federal Reserve
System, October 14, 2021.
Michele Taylor Fennell,
Deputy Associate Secretary of the Board.
[FR Doc. 2021–22769 Filed 10–18–21; 8:45 am]
BILLING CODE P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2021–22734 Filed 10–18–21; 8:45 am]
Centers for Disease Control and
Prevention
BILLING CODE 6712–01–P
[30Day–22–21GH]
FEDERAL RESERVE SYSTEM
Change in Bank Control Notices;
Acquisitions of Shares of a Bank or
Bank Holding Company
The notificants listed below have
applied under the Change in Bank
Control Act (Act) (12 U.S.C. 1817(j)) and
§ 225.41 of the Board’s Regulation Y (12
CFR 225.41) to acquire shares of a bank
or bank holding company. The factors
that are considered in acting on the
applications are set forth in paragraph 7
of the Act (12 U.S.C. 1817(j)(7)).
The public portions of the
applications listed below, as well as
other related filings required by the
Board, if any, are available for
immediate inspection at the Federal
Reserve Bank(s) indicated below and at
the offices of the Board of Governors.
This information may also be obtained
on an expedited basis, upon request, by
contacting the appropriate Federal
Reserve Bank and from the Board’s
Freedom of Information Office at
https://www.federalreserve.gov/foia/
request.htm. Interested persons may
express their views in writing on the
standards enumerated in paragraph 7 of
the Act.
Comments regarding each of these
applications must be received at the
Reserve Bank indicated or the offices of
the Board of Governors, Ann E.
Misback, Secretary of the Board, 20th
Street and Constitution Avenue NW,
Washington, DC 20551–0001, not later
than November 3, 2021.
A. Federal Reserve Bank of Chicago
(Colette A. Fried, Assistant Vice
President) 230 South LaSalle Street,
Chicago, Illinois 60690–1414:
1. The 2021 Katz Dynasty Trust,
Milwaukee, Wisconsin, Peter J. Wilder,
individually, and as trustee, Pewaukee,
Wisconsin; to join the Katz Family
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
Agency Forms Undergoing Paperwork
Reduction Act Review
In accordance with the Paperwork
Reduction Act of 1995, the Centers for
Disease Control and Prevention (CDC)
has submitted the information
collection request titled Using Real-time
Prescription and Insurance Claims Data
to Support the HIV Care Continuum to
the Office of Management and Budget
(OMB) for review and approval. CDC
previously published a ‘‘Proposed Data
Collection Submitted for Public
Comment and Recommendations’’
notice on July 12, 2021 to obtain
comments from the public and affected
agencies. CDC did not receive comments
related to the previous notice. This
notice serves to allow an additional 30
days for public and affected agency
comments.
CDC will accept all comments for this
proposed information collection project.
The Office of Management and Budget
is particularly interested in comments
that:
(a) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(b) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected;
(d) Minimize the burden of the
collection of information on those who
are to respond, including, through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
E:\FR\FM\19OCN1.SGM
19OCN1
57832
Federal Register / Vol. 86, No. 199 / Tuesday, October 19, 2021 / Notices
other forms of information technology,
e.g., permitting electronic submission of
responses; and
(e) Assess information collection
costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570.
Comments and recommendations for the
proposed information collection should
be sent within 30 days of publication of
this notice to www.reginfo.gov/public/
do/PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function. Direct written
comments and/or suggestions regarding
the items contained in this notice to the
Attention: CDC Desk Officer, Office of
Management and Budget, 725 17th
Street NW, Washington, DC 20503 or by
fax to (202) 395–5806. Provide written
comments within 30 days of notice
publication.
jspears on DSK121TN23PROD with NOTICES1
Proposed Project
Using Real-time Prescription and
Insurance Claims Data to Support the
HIV Care Continuum—New—National
Center for HIV/AIDS, Viral Hepatitis,
STD and TB Prevention (NCHHSTP),
Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
Use of HIV surveillance data to
identify out-of-care persons is one
strategy for identifying and re-engaging
out-of-care persons and is called Datato-Care (D2C). D2C uses laboratory
reports (i.e., CD4 and HIV viral load test
results) received by a health
department’s HIV surveillance program
as markers of HIV care. In the current
D2C model, there is a delay in the
identification of out-of-care persons due
to the time interval between
recommended monitoring tests (i.e.,
every three to six months) and the
subsequent reporting of these tests to
surveillance.
Insurance and prescription
administrative claims (billing) data can
be used to identify persons who fail to
fill antiretroviral (ARV) prescriptions
and who are at risk for falling out of
care. Because most ARVs are prescribed
as a 30-day supply of medication,
prescription claims can be used to
identify persons who are not filling ARV
prescriptions on a monthly basis.
Tracking ARV refill data can, therefore,
be a more real-time indicator of poor
adherence and can act as a harbinger of
potential poor retention in care. Using
real-time insurance and prescription
claims data to identify persons who fail
VerDate Sep<11>2014
17:51 Oct 18, 2021
Jkt 256001
to fill ARV prescriptions, and to
intervene, could have a significant
impact on ARV therapy adherence, viral
suppression and potentially on
retention in care.
The purpose of this information
collection, also called the Antiretroviral
Improvement among Medicaid Enrollees
(AIMS) study, is to develop, implement,
and evaluate a D2C strategy that uses
Medicaid insurance and prescription
claims data to identify; (1) persons with
HIV who have never been prescribed
ARV therapy, and (2) persons with HIV
who fail to pick up prescribed ARV
medications in a timely manner, and to
target these individuals for adherence
interventions.
A validated HIV case identification
algorithm will be applied to the Virginia
Medicaid database to identify persons
with HIV who have either never filled
an ARV prescription or have not filled
an ARV prescription within >30 to <90
days of the expected fill date.
Deterministic and probabilistic methods
will be used to link this list to the
Virginia Department of Health’s (VDH)
Care Markers database (an extract of the
VDH HIV surveillance database).
Individuals that are matched across the
two databases (indicating that the
persons are both enrolled in Medicaid
and confirmed HIV positive) are eligible
for study participation. Additional
eligibility criteria include age 19–63
years and continuous enrollment in
Virginia Medicaid for the preceding 12
months.
Cluster randomization will occur at
the healthcare provider level and will be
conducted concurrently with the initial
potential participant screening.
Providers will be randomized to either
the intervention arm or to the usual care
arm (i.e., no intervention or control
arm). Study participants are the patients
of the randomized healthcare providers.
Participants in the intervention arm will
be delegated to either a patient-level or
provider-level intervention, depending
on need; participants who are >30 to
<90 days late filling their ARV
prescription(s) will receive the patientlevel intervention and participants who
have never filled an ARV prescription
will be delegated to the provider-level
intervention. Participants of the
provider-level intervention will not
receive direct intervention. Instead, the
healthcare providers of these patients
(‘‘provider participants’’) will receive
the provider-level intervention.
Potential participants will be contacted
by a Study Linkage Coordinator to
explain the study and obtain consent for
participation.
The patient-level intervention has two
phases. Phase I is intended for patients
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
who are >30 to <60 days late filling their
ARV prescription(s). In Phase I, a
Linkage Coordinator will contact
participants to discuss the participants’
adherence barriers. Once the
participant’s adherence barriers are
identified, the participant will be
referred to appropriate resources to
assist them in overcoming their
adherence barrier(s). Phase II is
intended for patients who were enrolled
in Phase I but who failed to fill their
ARV prescriptions in the subsequent 30
days of the Phase I consultation, and for
participants who are >60 to <90 days
late at the time the participant was
determined to be study eligible. In
Phase II, the Linkage Coordinator will
lead a similar consultation as in Phase
I but will probe for more complex
adherence barriers (e.g., mental health
concerns) and referrals will be made
accordingly. The participant will also be
offered an evidence-informed mobile
application (‘‘app’’) which is designed
to support ART adherence and retention
in care.
The provider-level intervention will
consist of a peer-to-peer clinician
consultation delivered by clinicians
from the Virginia Department of
Health’s Advisory Committee to the
Virginia Medication Assistance Program
or by another HIV clinical expert. The
peer-to-peer clinician consultations will
involve introduction or reinforcement of
HIV clinical guidelines for ART
initiation, strategies to optimize ART
adherence, and resources for supporting
adherence for people with HIV. The
consultation will be tailored to the
needs of the provider participant.
All analyses will be conducted at the
patient level. Persons within the
intervention arm will be followed
prospectively for 12 months. At the end
of the intervention arm follow-up
period, persons within the usual care
arm will be followed retrospectively for
12 months. The primary study outcome
of HIV viral suppression (HIV RNA
<200 copies/mL) will be compared
between study arms.
CDC requests OMB approval to collect
standardized information, from 500
AIMS study participants (460
participants of the patient-level
intervention and 40 participants of the
provider-level intervention), 500
controls and 40 provider participants
over the three-year project period.
Secondary data will be abstracted from
the Virginia Medicaid and Virginia Care
Markers databases to determine study
eligibility, to conduct the patient- and
provider-level interventions, and to
determine study outcomes. During the
patient-level intervention, data will be
collected on participants’ adherence
E:\FR\FM\19OCN1.SGM
19OCN1
57833
Federal Register / Vol. 86, No. 199 / Tuesday, October 19, 2021 / Notices
barriers; this information will be used to
refer participants to appropriate
resources to assist their adherence to
ART. During the provider-level
intervention data will be collected to
inform the peer-to-peer clinician
consultation.
OMB approval is requested for three
years. Participation is voluntary and
there are no costs to respondents other
than their time. CDC requests approval
for an estimated 256 annualized burden
hours.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
responses
per
respondent
Average
burden per
response
(in hours)
Form name
Participants of patient-level intervention .........
Provider participants .......................................
Participants of provider-level intervention .......
Verbal consent—participants .........................
Verbal consent—provider participants ...........
Verbal consent—control participants (for participants of provider-level intervention).
Verbal consent—control participants .............
HIPPA authorization .......................................
HIPPA authorization .......................................
HIPPA authorization .......................................
PositiveLinks verbal consent and enrollment
Phase I interview ............................................
Phase II interview ...........................................
Clinician consultation guide ...........................
153
13
13
1
1
1
15/60
15/60
15/60
167
153
13
167
33
153
33
3
1
1
1
1
1
1
1
4
15/60
5/60
5/60
5/60
60/60
30/60
30/60
30/60
Clinician consultation guide ...........................
Post-consultation questionnaire .....................
13
3
1
4
30/60
10/60
Control participants .........................................
Participants of patient-level intervention .........
Participants of provider-level intervention .......
Control participants .........................................
PositiveLinks participants ................................
Participants of patient-level intervention .........
Participants of patient-level intervention .........
Advisory Committee to the Virginia Medication Assistance Program member and other
HIV clinical expects.
Provider participants .......................................
Advisory Committee to the Virginia Medication Assistance Program member and other
HIV clinical expects.
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2021–22695 Filed 10–18–21; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–22–0743]
Agency Forms Undergoing Paperwork
Reduction Act Review
jspears on DSK121TN23PROD with NOTICES1
Number of
respondents
Respondents
In accordance with the Paperwork
Reduction Act of 1995, the Centers for
Disease Control and Prevention (CDC)
has submitted the information
collection request titled Assessment and
Monitoring of Breastfeeding-Related
Maternity Care Practices in Intrapartum
Care Facilities in the United States and
Territories to the Office of Management
and Budget (OMB) for review and
approval. CDC previously published a
‘‘Proposed Data Collection Submitted
for Public Comment and
Recommendations’’ notice on March 19,
2021 to obtain comments from the
public and affected agencies. CDC
received two comments related to the
previous notice. This notice serves to
allow an additional 30 days for public
and affected agency comments.
VerDate Sep<11>2014
17:51 Oct 18, 2021
Jkt 256001
CDC will accept all comments for this
proposed information collection project.
The Office of Management and Budget
is particularly interested in comments
that:
(a) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(b) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected;
(d) Minimize the burden of the
collection of information on those who
are to respond, including, through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and
(e) Assess information collection
costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570.
Comments and recommendations for the
proposed information collection should
be sent within 30 days of publication of
this notice to www.reginfo.gov/public/
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
do/PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function. Direct written
comments and/or suggestions regarding
the items contained in this notice to the
Attention: CDC Desk Officer, Office of
Management and Budget, 725 17th
Street NW, Washington, DC 20503 or by
fax to (202) 395–5806. Provide written
comments within 30 days of notice
publication.
Proposed Project
Assessment and Monitoring of
Breastfeeding-Related Maternity Care
Practices in Intrapartum Care Facilities
in the United States and Territories
(OMB Control No. 0920–0743, Exp. 10/
31/2021)—Revision—National Center
for Chronic Disease Prevention and
Health Promotion (NCCDPHP), Centers
for Disease Control and Prevention
(CDC).
Background and Brief Description
Substantial evidence demonstrates the
social, economic, and health benefits of
breastfeeding for both the mother and
infant as well as for society in general.
Health professionals recommend at least
12 months of breastfeeding, and Healthy
People 2030 establishes specific
national breastfeeding goals. In addition
to increasing overall rates, a significant
public health priority in the U.S. is to
reduce variation in breastfeeding rates
E:\FR\FM\19OCN1.SGM
19OCN1
]]>Agencies
[Federal Register Volume 86, Number 199 (Tuesday, October 19, 2021)]
[Notices]
[Pages 57831-57833]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-22695]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-22-21GH]
Agency Forms Undergoing Paperwork Reduction Act Review
In accordance with the Paperwork Reduction Act of 1995, the Centers
for Disease Control and Prevention (CDC) has submitted the information
collection request titled Using Real-time Prescription and Insurance
Claims Data to Support the HIV Care Continuum to the Office of
Management and Budget (OMB) for review and approval. CDC previously
published a ``Proposed Data Collection Submitted for Public Comment and
Recommendations'' notice on July 12, 2021 to obtain comments from the
public and affected agencies. CDC did not receive comments related to
the previous notice. This notice serves to allow an additional 30 days
for public and affected agency comments.
CDC will accept all comments for this proposed information
collection project. The Office of Management and Budget is particularly
interested in comments that:
(a) Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
(b) Evaluate the accuracy of the agencies estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and clarity of the information to
be collected;
(d) Minimize the burden of the collection of information on those
who are to respond, including, through the use of appropriate
automated, electronic, mechanical, or other technological collection
techniques or
[[Page 57832]]
other forms of information technology, e.g., permitting electronic
submission of responses; and
(e) Assess information collection costs.
To request additional information on the proposed project or to
obtain a copy of the information collection plan and instruments, call
(404) 639-7570. Comments and recommendations for the proposed
information collection should be sent within 30 days of publication of
this notice to www.reginfo.gov/public/do/PRAMain. Find this particular
information collection by selecting ``Currently under 30-day Review--
Open for Public Comments'' or by using the search function. Direct
written comments and/or suggestions regarding the items contained in
this notice to the Attention: CDC Desk Officer, Office of Management
and Budget, 725 17th Street NW, Washington, DC 20503 or by fax to (202)
395-5806. Provide written comments within 30 days of notice
publication.
Proposed Project
Using Real-time Prescription and Insurance Claims Data to Support
the HIV Care Continuum--New--National Center for HIV/AIDS, Viral
Hepatitis, STD and TB Prevention (NCHHSTP), Centers for Disease Control
and Prevention (CDC).
Background and Brief Description
Use of HIV surveillance data to identify out-of-care persons is one
strategy for identifying and re-engaging out-of-care persons and is
called Data-to-Care (D2C). D2C uses laboratory reports (i.e., CD4 and
HIV viral load test results) received by a health department's HIV
surveillance program as markers of HIV care. In the current D2C model,
there is a delay in the identification of out-of-care persons due to
the time interval between recommended monitoring tests (i.e., every
three to six months) and the subsequent reporting of these tests to
surveillance.
Insurance and prescription administrative claims (billing) data can
be used to identify persons who fail to fill antiretroviral (ARV)
prescriptions and who are at risk for falling out of care. Because most
ARVs are prescribed as a 30-day supply of medication, prescription
claims can be used to identify persons who are not filling ARV
prescriptions on a monthly basis. Tracking ARV refill data can,
therefore, be a more real-time indicator of poor adherence and can act
as a harbinger of potential poor retention in care. Using real-time
insurance and prescription claims data to identify persons who fail to
fill ARV prescriptions, and to intervene, could have a significant
impact on ARV therapy adherence, viral suppression and potentially on
retention in care.
The purpose of this information collection, also called the
Antiretroviral Improvement among Medicaid Enrollees (AIMS) study, is to
develop, implement, and evaluate a D2C strategy that uses Medicaid
insurance and prescription claims data to identify; (1) persons with
HIV who have never been prescribed ARV therapy, and (2) persons with
HIV who fail to pick up prescribed ARV medications in a timely manner,
and to target these individuals for adherence interventions.
A validated HIV case identification algorithm will be applied to
the Virginia Medicaid database to identify persons with HIV who have
either never filled an ARV prescription or have not filled an ARV
prescription within >30 to <90 days of the expected fill date.
Deterministic and probabilistic methods will be used to link this list
to the Virginia Department of Health's (VDH) Care Markers database (an
extract of the VDH HIV surveillance database). Individuals that are
matched across the two databases (indicating that the persons are both
enrolled in Medicaid and confirmed HIV positive) are eligible for study
participation. Additional eligibility criteria include age 19-63 years
and continuous enrollment in Virginia Medicaid for the preceding 12
months.
Cluster randomization will occur at the healthcare provider level
and will be conducted concurrently with the initial potential
participant screening. Providers will be randomized to either the
intervention arm or to the usual care arm (i.e., no intervention or
control arm). Study participants are the patients of the randomized
healthcare providers. Participants in the intervention arm will be
delegated to either a patient-level or provider-level intervention,
depending on need; participants who are >30 to <90 days late filling
their ARV prescription(s) will receive the patient-level intervention
and participants who have never filled an ARV prescription will be
delegated to the provider-level intervention. Participants of the
provider-level intervention will not receive direct intervention.
Instead, the healthcare providers of these patients (``provider
participants'') will receive the provider-level intervention. Potential
participants will be contacted by a Study Linkage Coordinator to
explain the study and obtain consent for participation.
The patient-level intervention has two phases. Phase I is intended
for patients who are >30 to <60 days late filling their ARV
prescription(s). In Phase I, a Linkage Coordinator will contact
participants to discuss the participants' adherence barriers. Once the
participant's adherence barriers are identified, the participant will
be referred to appropriate resources to assist them in overcoming their
adherence barrier(s). Phase II is intended for patients who were
enrolled in Phase I but who failed to fill their ARV prescriptions in
the subsequent 30 days of the Phase I consultation, and for
participants who are >60 to <90 days late at the time the participant
was determined to be study eligible. In Phase II, the Linkage
Coordinator will lead a similar consultation as in Phase I but will
probe for more complex adherence barriers (e.g., mental health
concerns) and referrals will be made accordingly. The participant will
also be offered an evidence-informed mobile application (``app'') which
is designed to support ART adherence and retention in care.
The provider-level intervention will consist of a peer-to-peer
clinician consultation delivered by clinicians from the Virginia
Department of Health's Advisory Committee to the Virginia Medication
Assistance Program or by another HIV clinical expert. The peer-to-peer
clinician consultations will involve introduction or reinforcement of
HIV clinical guidelines for ART initiation, strategies to optimize ART
adherence, and resources for supporting adherence for people with HIV.
The consultation will be tailored to the needs of the provider
participant.
All analyses will be conducted at the patient level. Persons within
the intervention arm will be followed prospectively for 12 months. At
the end of the intervention arm follow-up period, persons within the
usual care arm will be followed retrospectively for 12 months. The
primary study outcome of HIV viral suppression (HIV RNA <200 copies/mL)
will be compared between study arms.
CDC requests OMB approval to collect standardized information, from
500 AIMS study participants (460 participants of the patient-level
intervention and 40 participants of the provider-level intervention),
500 controls and 40 provider participants over the three-year project
period. Secondary data will be abstracted from the Virginia Medicaid
and Virginia Care Markers databases to determine study eligibility, to
conduct the patient- and provider-level interventions, and to determine
study outcomes. During the patient-level intervention, data will be
collected on participants' adherence
[[Page 57833]]
barriers; this information will be used to refer participants to
appropriate resources to assist their adherence to ART. During the
provider-level intervention data will be collected to inform the peer-
to-peer clinician consultation.
OMB approval is requested for three years. Participation is
voluntary and there are no costs to respondents other than their time.
CDC requests approval for an estimated 256 annualized burden hours.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of burden per
Respondents Form name respondents responses per response (in
respondent hours)
----------------------------------------------------------------------------------------------------------------
Participants of patient-level Verbal consent-- 153 1 15/60
intervention. participants.
Provider participants................. Verbal consent--provider 13 1 15/60
participants.
Participants of provider-level Verbal consent--control 13 1 15/60
intervention. participants (for
participants of
provider-level
intervention).
Control participants.................. Verbal consent--control 167 1 15/60
participants.
Participants of patient-level HIPPA authorization..... 153 1 5/60
intervention.
Participants of provider-level HIPPA authorization..... 13 1 5/60
intervention.
Control participants.................. HIPPA authorization..... 167 1 5/60
PositiveLinks participants............ PositiveLinks verbal 33 1 60/60
consent and enrollment.
Participants of patient-level Phase I interview....... 153 1 30/60
intervention.
Participants of patient-level Phase II interview...... 33 1 30/60
intervention.
Advisory Committee to the Virginia Clinician consultation 3 4 30/60
Medication Assistance Program member guide.
and other HIV clinical expects.
Provider participants................. Clinician consultation 13 1 30/60
guide.
Advisory Committee to the Virginia Post-consultation 3 4 10/60
Medication Assistance Program member questionnaire.
and other HIV clinical expects.
----------------------------------------------------------------------------------------------------------------
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Scientific
Integrity, Office of Science, Centers for Disease Control and
Prevention.
[FR Doc. 2021-22695 Filed 10-18-21; 8:45 am]
BILLING CODE 4163-18-P
